US 12,435,157 B2
Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers
Diana F. Hausman, Seattle, WA (US); Neil C. Josephson, Seattle, WA (US); Rose Kamyee Lai, Seattle, WA (US); Gerald James Rowse, Vancouver (CA); and Patrick Kaminker, Seattle, WA (US)
Assigned to ZYMEWORKS BC INC., Vancouver (CA)
Filed by ZYMEWORKS BC INC., Vancouver (CA)
Filed on Nov. 19, 2021, as Appl. No. 17/530,775.
Application 17/530,775 is a continuation of application No. PCT/US2019/035042, filed on May 31, 2019.
Prior Publication US 2022/0133903 A1, May 5, 2022
Int. Cl. C07K 16/32 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01)
CPC C07K 16/32 (2013.01) [A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 47/545 (2017.08); A61K 47/68031 (2023.08); A61K 47/6817 (2017.08); A61K 47/6851 (2017.08); A61K 39/00 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01)] 26 Claims
OG exemplary drawing
 
1. A method of treating a subject with HER2-positive biliary tract cancer (BTC), comprising administering an effective amount of a bispecific anti-HER2 antigen-binding construct comprising a heavy chain H1 comprising the amino acid sequence set forth in SEQ ID NO:36, a heavy chain H2 comprising the amino acid sequence set forth in SEQ ID NO:63, and a light chain L1 comprising the amino acid sequence set forth in SEQ ID NO:24 to the subject.